Huang Wenli, Zhu Wenyi, Lin Yu, Chan Francis K L, Xu Zhilu, Ng Siew C
Microbiota I-Center (MagIC), Hong Kong, China.
Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.
Gut Microbes. 2025 Dec;17(1):2467193. doi: 10.1080/19490976.2025.2467193. Epub 2025 Feb 20.
Next-generation live biotherapeutics are promising to aid the treatment of obesity and metabolic diseases. Here, we reported a novel anti-obesity probiotic candidate, , that was depleted in stool samples of obese subjects compared with lean controls, and its abundance was negatively correlated with body mass index and serum triglycerides. Supplementation of prevented body weight gain and disorders of glucose and lipid metabolism, prevented fatty liver, inhibited white adipose tissue expansion and brown adipose tissue whitening in mice fed with high-fat diet, and boosted the abundance of lean-related species. The effects of could be partially attributed to the production of nicotinamide riboside and upregulation of the Sirtuin1/mTOR signaling pathway. These results indicated that s is a promising candidate for the development of next-generation live biotherapeutics for the prevention of obesity and metabolic diseases.
下一代活体生物治疗药物有望辅助治疗肥胖症和代谢性疾病。在此，我们报告了一种新型抗肥胖益生菌候选物，与瘦对照组相比，该候选物在肥胖受试者的粪便样本中含量较低，且其丰度与体重指数和血清甘油三酯呈负相关。补充该候选物可防止体重增加以及葡萄糖和脂质代谢紊乱，预防脂肪肝，抑制高脂饮食喂养小鼠的白色脂肪组织扩张和棕色脂肪组织白化，并提高与瘦相关物种的丰度。该候选物的作用可能部分归因于烟酰胺核糖的产生以及Sirtuin1/mTOR信号通路的上调。这些结果表明，该候选物是开发预防肥胖症和代谢性疾病的下一代活体生物治疗药物的有前景的候选物。
